Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.42 |
| ▸ | ICMT | O60725 | 5/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15043677 | 0.84 | S1PR1 (0.42) | S1PR1ICMTP2RX7S1PR3ITGA4 | |
| SCHEMBL10178167 | 0.74 | ICMT (0.43) | ICMTP2RX7OPRM1 | |
| SCHEMBL25769266 | 0.72 | P2RX7 (0.42) | S1PR1P2RX7S1PR3OPRM1OPRL1 | |
| SCHEMBL7011113 | 0.69 | CHRNA7 (0.43) | S1PR1P2RX7S1PR3OPRM1OPRL1 | |
| SCHEMBL2425379 | 0.69 | ALDH1A1 (0.51) | KCNH2OPRM1OPRL1 | |
| SCHEMBL12199577 | 0.69 | ALOX5 (0.44) | ITGA4ITGB7 | |
| SCHEMBL18730765 | 0.69 | CHRNB2 (0.44) | S1PR1P2RX7S1PR3OPRM1OPRL1 | |
| SCHEMBL20087030 | 0.69 | ALDH1A1 (0.44) | P2RX7OPRM1OPRL1 | |
| SCHEMBL10178154 | 0.69 | ICMT (0.36) | ICMTOPRM1OPRL1 | |
| SCHEMBL25062630 | 0.66 | P2RX7 (0.51) | S1PR1P2RX7S1PR3OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822510-B2 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | disclosed |
| WO-2012012477-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885ICMT 4727/4885P2RX7 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.